MDWD · MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

42 Hayarkon Street, Yavne, 8122745, Israel
Biotechnology
Healthcare

Market Cap

194.8M

52 Wk Range

$11.80 - $19.70

Previous Close

$13.54

Open

$13.48

Volume

63,751

Day Range

$13.36 - $13.62

Enterprise Value

176.2M

Cash

27.85M

Avg Qtr Burn

-7.65M

Insider Ownership

15.47%

Institutional Own.

54.33%

Qtr Updated

Sep 30th 2026